Spiroazacyclic compounds as monoamine receptor modulators

Details Spiroazacyclic compounds as monoamine receptor modulators Spiroazacyclic compounds as monoamine receptor modulators

2009-01-27

2010-06-01

Habte, Kahsay T (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S017000, C546S018000

Reexamination Certificate

active

07727999

ABSTRACT:
The present invention relates to optionally substituted 1,3,8-triaza-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

REFERENCES:
patent: 3983234 (1976-09-01), Sayers
patent: 4138492 (1979-02-01), Noverola et al.
patent: 4255432 (1981-03-01), Kluge et al.
patent: 4332804 (1982-06-01), Clark
patent: 4353900 (1982-10-01), Clark
patent: 4353901 (1982-10-01), Clark
patent: 4367232 (1983-01-01), Boix-Igleasias et al.
patent: 4853394 (1989-08-01), King et al.
patent: 5025013 (1991-06-01), Barreau et al.
patent: 5214055 (1993-05-01), Peglion et al.
patent: 5216165 (1993-06-01), Mobilio et al.
patent: 5461066 (1995-10-01), Gericke et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5707798 (1998-01-01), Brann
patent: 5795894 (1998-08-01), Shue et al.
patent: 5869488 (1999-02-01), Shue et al.
patent: 5877173 (1999-03-01), Olney et al.
patent: 5912132 (1999-06-01), Brann
patent: 5955281 (1999-09-01), Brann
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6248756 (2001-06-01), Anthony et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 6399619 (2002-06-01), Berk et al.
patent: 6756393 (2004-06-01), Andersson et al.
patent: 6815458 (2004-11-01), Andersson et al.
patent: 6911452 (2005-06-01), Schlienger
patent: 7022698 (2006-04-01), Hamied et al.
patent: 7041667 (2006-05-01), Armour et al.
patent: 7115634 (2006-10-01), Thurieau et al.
patent: 7217719 (2007-05-01), Schlienger
patent: 7253186 (2007-08-01), Andersson et al.
patent: 7351707 (2008-04-01), Schlienger
patent: 7402590 (2008-07-01), Schlienger
patent: 7476682 (2009-01-01), Andersson et al.
patent: 7511053 (2009-03-01), Schlienger
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0106600 (2004-06-01), Andersson et al.
patent: 2004/0213816 (2004-10-01), Weiner et al.
patent: 2005/0014757 (2005-01-01), Andersson et al.
patent: 2005/0148018 (2005-07-01), Weiner et al.
patent: 2005/0244862 (2005-11-01), Brann
patent: 2005/0256108 (2005-11-01), Schlienger
patent: 2006/0094758 (2006-05-01), Andersson et al.
patent: 2006/0106063 (2006-05-01), Thygesen et al.
patent: 2006/0111399 (2006-05-01), Thygesen et al.
patent: 2006/0194778 (2006-08-01), Andersson et al.
patent: 2006/0194834 (2006-08-01), Andersson et al.
patent: 2006/0199794 (2006-09-01), Schlienger
patent: 2006/0199818 (2006-09-01), Andersson et al.
patent: 2006/0199842 (2006-09-01), Weiner et al.
patent: 2006/0205710 (2006-09-01), Schlienger
patent: 2006/0205722 (2006-09-01), Andersson et al.
patent: 2006/0205780 (2006-09-01), Thygesen et al.
patent: 2006/0205781 (2006-09-01), Thygesen et al.
patent: 2006/0264465 (2006-11-01), Weiner et al.
patent: 2006/0264466 (2006-11-01), Weiner et al.
patent: 2006/0286610 (2006-12-01), Brann
patent: 2006/0292606 (2006-12-01), Brann
patent: 2007/0161621 (2007-07-01), Schienger
patent: 2009/0131418 (2009-05-01), Schienger
patent: 2009/0186921 (2009-07-01), Andersson et al.
patent: 984843 (1976-03-01), None
patent: 0 005 318 (1979-11-01), None
patent: 0 061 333 (1982-09-01), None
patent: 0 379 441 (1990-07-01), None
patent: 0 548 015 (1993-06-01), None
patent: 0 260 070 (1993-08-01), None
patent: 0 625 507 (1994-11-01), None
patent: 2802206 (2001-06-01), None
patent: 157325 (1998-03-01), None
patent: 09-503491 (1997-04-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 95/03303 (1995-02-01), None
patent: WO 97/08166 (1997-03-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/17646 (1998-04-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/56335 (2000-09-01), None
patent: WO 00/59497 (2000-10-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 01/44191 (2001-06-01), None
patent: WO 01/66521 (2001-09-01), None
patent: WO 01/87839 (2001-11-01), None
patent: WO 02/079186 (2002-10-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/086400 (2003-10-01), None
patent: WO 04/000808 (2003-12-01), None
patent: WO 04/000808 (2003-12-01), None
patent: WO 2004/009549 (2004-01-01), None
patent: WO 2004/039322 (2004-05-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064753 (2004-08-01), None
patent: WO 2004/072034 (2004-08-01), None
patent: WO 2005/063254 (2005-07-01), None
patent: WO 2005/112927 (2005-12-01), None
patent: WO 2006/036874 (2006-04-01), None
patent: WO 2006/037043 (2006-04-01), None
Adam, et al. 1989. Effects of repeated ritanserin on middle-aged poor sleepers.Psychopharmacology, 99:219-221.
Adell, et al. 2005. Strategies for producing faster acting antidepressants.Drug Discovery Today, 10(8):578-585.
Akin, et al. 2004. Decreased serotonin 5-HT2Areceptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients.Neuropsychopharmacology, 29:2081-2087.
Alvisi, N. 1892. Sulla formazione di derivati pirazolici dalle dicloridrine e dalla tribromidrina della glicerina ordinaria,Gazz. Chem. Ital. 22:158-168.
Antilla, et al. 2001. Copper-catalyzed coupling of arylboronic acids and amines.Organic Letters, 3(13):2077-2079.
Antilla, et al. 2002. The copper-catalyzed N-arylation of indoles.J. Am. Chem. Soc., 124:11684-11688.
Archibald, et al., 1974 “Benzamidopiperdines. 2. Heterocyclic Compounds Related to Indoramin”J. Medicinal Chemistry, 17(7):736-739.
Archibald, et al., 1974 “Benzamidopiperdines. 3. Heterocyclic Compounds Related to Indoramin” J. Medicinal Chemistry, 17(7):-739-744.
Archibald, et al., 1974 “1,4-Bis-(2-indol-3-ylethyl)piperdines” J. Medicinal Chemistry, 17(7):-745-747.
Artico, et al. 1992. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase.Eur. J. Med. Chem., 27:219-228.
Bakshi, et al. 1994. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response.The Journal of Pharmacology and Experimental Therapeutics, 271(2):787-794.
Barchas, J. 1973.Serotonin and Behavior. New York: Academic Press.
Barnes, et al. 1999. A review of central 5-HT receptors and their function.Neuropharmacology, 38:1083-1152.
Barr, et al. 1997. Agonist-independent activation of Gzby the 5-hydroxytryptamine1Areceptor co-expressed inSpodoptera frugiperdacells.The Journal of Biological Chemistry, 272(52):32979-32987.
Bassus, et al. 1974. Psychotropes potentiels. X. Synthèse de butyrophénones à cycle pipéridine-spiro-tétrahydrooxazinone douées d'activité neuroleptique.Eur. J. Med. Chem.—Chimica Therapeutica, 9(4):416-423.
Bennett, et al. 1993. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms.Neurology, 43:1551-1555.
Bhatia, et al. 1996. 5-Lipoxygenase inhibitors: Synthesis and structure-activity relationships of a series of 1-Aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones.J. Med. Chem., 39:3938-3950.
Biagi, et al. 1988. 1,2,3-Triazoles: Structural changes on two effective inhibitors of the prostaglandin synthesis in vitro.Farmaco Ed. Sci., 43:597-612.
Bibbiani, et al. 2001. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.Neurology, 57:1829-1834.
Birkmayer, et al. 1974. Nucleus ruber and L-Dopa psychosis: Biochemical post-mortem findings.Journal of Neural Transmission, 35:93-116.
Blakley, et

Affiliated with

Also associated with

Rating

Spiroazacyclic compounds as monoamine receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Spiroazacyclic compounds as monoamine receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spiroazacyclic compounds as monoamine receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4219426